DEI Contact Us
Improve diversity and inclusion in clinical research with Advarra’s global expertise in DE&I planning and recruitment strategy development.
Improve diversity and inclusion in clinical research with Advarra’s global expertise in DE&I planning and recruitment strategy development.
The International Council for Harmonisation (ICH) good clinical practice (GCP) guidelines are critical in ensuring the safety and rights of
Advarra’s GxP services offer tailored support for every trial phase, ensuring seamless execution from startup to closeout for global therapeutic delivery.
Advarra provides tailored consulting services to revitalize your HRPP, ensuring it meets your unique objectives and thrives in a complex regulatory landscape.
Achieving diversity, equity, and inclusion (DEI) in clinical trials is crucial for producing comprehensive and effective medical research benefitting all
At institutional research programs around the U.S., there exists a pervasive myth: internal institutional review board (IRB) reviews are free.
Navigating cGMP application in investigational drugs can be complex. Learn how FDA guidelines help clinical teams maintain safety and quality from early trials to commercialization.
As sIRB mandates reshape the clinical trial landscape, study teams must navigate unique challenges while ensuring compliance and participant protection.
Maintaining complete and compliant documentation while managing the complex processes and interactions of clinical trial conduct can be complicated. This blog outlines the details to look out for preparing your investigator site file (ISF) for an audit.Â
Interim staffing offers HRPPs specialized expertise, fresh perspectives, and support for accreditation and structural improvements without disrupting daily operations.
The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While
Explore the state of DE&I in clinical research with survey insights on diversity plans, budgeting efforts, and progress in trial representation.